Combo OTC Drug Labeling Deadlines To Be Addressed In Final Monographs
This article was originally published in The Tan Sheet
Executive Summary
FDA will take into account OTC labeling reg compliance deadlines when publishing final monographs that could subject combination products to frequent relabeling, the agency says in a June 20 Federal Register notice extending by one year implementation provisions for specific types of OTCs.
You may also be interested in...
OTC Antitussive Flammability, Burn Warnings Added To Final Monograph
Cautionary statements regarding flammability and burns for topical/inhalant products containing camphor or menthol must appear under the "Warnings" section of product labeling, FDA says in amending the OTC antitussive drugs final monograph.
OTC Antitussive Flammability, Burn Warnings Added To Final Monograph
Cautionary statements regarding flammability and burns for topical/inhalant products containing camphor or menthol must appear under the "Warnings" section of product labeling, FDA says in amending the OTC antitussive drugs final monograph.
OTC Antitussive Flammability, Burn Warnings Added To Final Monograph
Cautionary statements regarding flammability and burns for topical/inhalant products containing camphor or menthol must appear under the "Warnings" section of product labeling, FDA says in amending the OTC antitussive drugs final monograph.